Across TCGA pan-cancer cohorts, SDHAP3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SDHAP3 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SDHAP3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SDHAP3 expression acts as an unfavorable survival marker.
ACC are the cancer types where SDHAP3 Mutation most reproducibly stratifies survival.